Background/Objectives: Myocardial infarction (MI) and diabetes pose significant health challenges globally, necessitating the development of innovative medication strategies to improve outcomes in affected populations. This research aimed to determine the defensive impact of ferulic acid (FA) against isoproterenol-induced myocardial infarction (MI) in diabetic rats. Methods: A group of male rats was partitioned into five distinct groups: control group, diabetic group, diabetic + MI, diabetic + MI + 20 mg/kg FA, and diabetic + MI + 40 mg/kg FA. The experimental groups received isoproterenol (ISO) subcutaneously at a dosage of 50 mg/kg body weight for two consecutive days. Results: The outcome was severe cardiac toxicity, as shown by changes in electrocardiogram (ECG) rhythm and a substantial increase in blood cardiac enzymes such as creatinine kinase (CK-MB), cardiac troponin I (cTnI), and lactate dehydrogenase (LDH). Additionally, there was a surge in inflammatory cytokines, like tumor necrosis factor-alpha (TNF-α), and a disruption of the antioxidant system, evidenced by a rise in malondialdehyde (MDA) content. Moreover, there was a rise in cardiac receptor of advanced glycation end products (RAGE). Treatment with FA with escalating dosages of 20 and 40 mg/kg b.w. effectively mitigated changes in serum cardiac enzymes and improved the cellular architecture, which was evaluated by histopathological examination. Conclusions: In conclusion, in a dose-dependent manner, FA successfully showed a cardioprotective effect against ISO-induced cardiac toxicity in diabetic rats, as shown by the improvement in ECG findings, normalization of serum cardiac biomarkers, and augmentation of the endogenous antioxidant system. Therefore, the aforementioned data indicate that ferulic acid may potentially have a protective effect on MI patients who have diabetes mellitus.

Diabetes mellitus (DM) is marked by hyperglycemia. An association has been discovered between extended durations of elevated blood glucose levels and a higher occurrence of both micro-and macrovascular diseases in individuals with diabetes. This correlation is present even after achieving glycemic control, indicating an inherent process known as "metabolic memory." Advanced glycation end products (AGEs) are proteins that have undergone glycation and are believed to have a role in metabolic memory. They are produced more in the presence of excessive blood glucose levels and have a sluggish turnover rate. Increased levels of AGEs may cause aberrant cross-linking of proteins in both the extracellular and intracellular spaces, resulting in disruptions in their typical arrangement and function. In addition, the activation of AGE receptor may initiate intricate signalling pathways that result in heightened oxidative stress, inflammation, elevated calcium deposition, and enhanced vascular smooth muscle cell death. All of these variables together lead to the advancement of atherosclerosis. AGEs are likely to substantially impact the increasing prevalence of cardiovascular disease (CVD). Furthermore, it is crucial to explore novel treatment strategies that specifically target AGEs and associated pathways in order to mitigate and treat CVD in individuals with diabetes metabolic disorders, with the goal of improving clinical results.